Human LincRNAs in Macrophage Biology and Related Cardiometabolic Diseases

巨噬细胞生物学和相关心脏代谢疾病中的人类 LincRNA

基本信息

  • 批准号:
    9402855
  • 负责人:
  • 金额:
    $ 72.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2021-07-31
  • 项目状态:
    已结题

项目摘要

Most human complex trait genetic signals lie in intergenic regions, implicating regulatory elements, including long intergenic non-coding RNAs (lincRNAs). These are typically not conserved in mouse and often cell-specific, raising challenges to mechanistic study but also providing a major opportunity for advances in human health and disease. Here, we embrace this challenge in interrogation of three non-conserved lincRNAs that we prioritized from deep RNAseq and preliminary functional studies in human macrophages. Macrophage activation to diverse functional states plays a central role in cardiometabolic diseases (CMD). We hypothesize that human lincRNAs modulate macrophage inflammatory and metabolic functions that impact complex CMD. To date regulatory effects of a few lincRNAs on macrophage biology have been reported, but the vast majority of human macrophage lincRNAs has yet to be studied. Through RNAseq of primary human monocyte-derived macrophages (HMDM), we identified 2,776 multi-exon lincRNAs of which >80% are not annotated in mouse. Based on (i) modulation during macrophage activation, (ii) overlap with genetic signals for CMD, (iii) macrophage enrichment and abundance, (iv) ChIP-seq binding of CEBPa and PU.1 proteins, and (v) similar expression pattern in human induced pluripotent stem cells (hiPSC) derived macrophages (IPSDM), we selected a set of 22 lincRNAs for validation and preliminary translation. From these, we focus here on three lincRNAs, not expressed in mouse macrophages, that have preliminary evidence of human macrophage functions. RP11-10J5.1 is markedly induced during inflammatory M1 activation, has increased expression in human atherosclerosis and attenuates iNOS expression and apoptosis (Aim 1). In contrast, RP11-184M15.1 is highly induced during M2 macrophage activation and modulates M2 phenotype (Aim 2). Finally, RP11-472N13.3 associates with central human obesity and attenuates macrophage IFNg signaling (Aim 3). Because large-scale genetic manipulation in primary human macrophages is limiting, we propose CRISPR/Cas9 gene-editing in IPSDM to pursue functional genomic interrogations of these CMD-relevant lincRNAs. Key findings will be corroborated by knockdown (KD) and overexpression (OE) of lincRNAs in HMDM. Localization, miR binding and protein interactions will be defined by RNA fluorescence in situ hybridization, MS2-tagged RNA affinity purification, confirmed with QPCR, and pull-down with biotinylated lincRNA probes coupled to mass-spectrometry and with RNA immunoprecipitation. KD and OE of interacting partners will test lincRNAs functional roles via specific miR or proteins target(s). Human disease relevance will be determined by localizing lincRNAs to macrophages in coronary atherosclerosis and visceral adipose and through interrogation of lincRNA cis-regulatory variants, identified via macrophage allele specific expression, in CMD genetic datasets.
大多数人类复杂的性状遗传信号存在于基因间隔区,涉及调控元件,包括 长的基因间非编码RNA(LincRNAs)。它们通常在小鼠中不保守,通常是细胞特异性的, 对机械学研究提出了挑战,但也为人类健康和 疾病。在这里,我们接受了这一挑战,询问了我们优先考虑的三个非保守的lincRNA 来自深层RNAseq和人类巨噬细胞的初步功能研究。巨噬细胞活化到多种 功能状态在心脏代谢性疾病(CMD)中起着核心作用。我们假设人类的LincRNA 调节巨噬细胞炎症和代谢功能,从而影响复杂的CMD。到目前为止的监管 一些lincRNA对巨噬细胞生物学的影响已有报道,但绝大多数人类 巨噬细胞的lincRNAs还有待研究。通过原代人单核细胞来源的RNAseq 巨噬细胞(HMDM),我们鉴定了2,776个多外显子连接RNA,其中80%在小鼠中没有注释。 基于(I)巨噬细胞激活期间的调节,(Ii)与CMD的遗传信号重叠,(Iii)巨噬细胞 (4)CEBPA和PU.1蛋白的ChIP-seq结合;(V)相似表达 在人类诱导多能干细胞(HiPSC)来源的巨噬细胞(IPSDM)中,我们选择了一组22 用于验证和初步翻译的lincRNA。在此,我们关注三个未表达的lincRNAs 在小鼠巨噬细胞中,具有人类巨噬细胞功能的初步证据。RP11-10J5.1是 在炎性M1激活过程中显著诱导,在人类动脉粥样硬化和 减少iNOS表达和细胞凋亡(目标1)。相反,RP11-184M15.1在M2期间高度诱导 巨噬细胞激活和调节M2表型(目标2)。最后,RP11-472N13.3与中央 人类肥胖和减弱巨噬细胞IFNG信号(目标3)。因为大规模的基因操作 在原代人巨噬细胞中是有限的,我们建议在IPSDM中进行CRISPR/Cas9基因编辑来追求 这些与CMD相关的lincRNAs的功能基因组询问。关键发现将得到以下方面的证实 HMDM中lincRNAs的敲除(KD)和过表达(OE)。定位、miR结合与蛋白质 相互作用将通过RNA荧光原位杂交、MS2标记的RNA亲和纯化、 用定量聚合酶链式反应确认,并用生物素化lincRNA探针与质谱仪和 RNA免疫沉淀。互动伙伴的KD和OE将通过特定的miR测试lincRNAs的功能角色 或蛋白质靶标(S)。人类疾病的相关性将通过在巨噬细胞中定位lincRNAs来确定 冠状动脉粥样硬化和内脏脂肪以及通过询问lincRNA顺式调节变异体, 在CMD基因数据集中,通过巨噬细胞等位基因的特异性表达进行鉴定。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Muredach P Reilly其他文献

Single-cell multimodal profiling of monocytes reveals diverse phenotypes and alterations linked to cardiovascular disease risks
单核细胞的单细胞多模式分析揭示了与心血管疾病风险相关的多种表型和变化
  • DOI:
    10.1101/2024.02.18.580913
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Alexander C. Bashore;Chenyi Xue;Eunyoung Kim;Hanying Yan;Lucie Y. Zhu;Huize Pan;Michael D Kissner;Leila S Ross;Hanrui Zhang;Mingyao Li;Muredach P Reilly
  • 通讯作者:
    Muredach P Reilly
1008-184 The effects of pravastatin and atorvastatin on markers of oxidant stress in vivo
  • DOI:
    10.1016/s0735-1097(04)91877-3
  • 发表时间:
    2004-03-03
  • 期刊:
  • 影响因子:
  • 作者:
    Bonnie Ky;Megan L Wolfe;Anne Burke;Philippe O Szapary;Muredach P Reilly;Jennifer B Dykhouse;Leanne T Bloedon;Garret A FitzGerald;Daniel J Rader
  • 通讯作者:
    Daniel J Rader

Muredach P Reilly的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Muredach P Reilly', 18)}}的其他基金

Smooth muscle cell-derived cell fates and cellular interactions in atherosclerotic plaque stability in disease progression and regression.
平滑肌细胞衍生的细胞命运和细胞相互作用在疾病进展和消退中动脉粥样硬化斑块的稳定性。
  • 批准号:
    10567844
  • 财政年份:
    2023
  • 资助金额:
    $ 72.21万
  • 项目类别:
Identification of smooth muscle cell genes causal in atherosclerotic plaque stability and cardiovascular disease risk
鉴定导致动脉粥样硬化斑块稳定性和心血管疾病风险的平滑肌细胞基因
  • 批准号:
    10720225
  • 财政年份:
    2023
  • 资助金额:
    $ 72.21万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10674531
  • 财政年份:
    2022
  • 资助金额:
    $ 72.21万
  • 项目类别:
Human LincRNAs in Macrophage Biology and Related Cardiometabolic Diseases
巨噬细胞生物学和相关心脏代谢疾病中的人类 LincRNA
  • 批准号:
    9983136
  • 财政年份:
    2017
  • 资助金额:
    $ 72.21万
  • 项目类别:
Human LincRNAs in Macrophage Biology and Related Cardiometabolic Diseases
巨噬细胞生物学和相关心脏代谢疾病中的人类 LincRNA
  • 批准号:
    9531432
  • 财政年份:
    2017
  • 资助金额:
    $ 72.21万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10349079
  • 财政年份:
    2016
  • 资助金额:
    $ 72.21万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10439923
  • 财政年份:
    2016
  • 资助金额:
    $ 72.21万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    9309130
  • 财政年份:
    2016
  • 资助金额:
    $ 72.21万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10199125
  • 财政年份:
    2016
  • 资助金额:
    $ 72.21万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    9932779
  • 财政年份:
    2016
  • 资助金额:
    $ 72.21万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 72.21万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 72.21万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 72.21万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 72.21万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 72.21万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 72.21万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 72.21万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 72.21万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 72.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 72.21万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了